2C2-NBOMe

2C2-NBOMe

Clinical data
Other names	NBOMe-MMDPEA-2; MMDPEA-2-NBOMe; 2C-MMDA-2-NBOMe; 2C-2-NBOMe; N-(2-Methoxybenzyl)-2-methoxy-4,5-methylenedioxyphenethylamine
Drug class	Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None
Identifiers
IUPAC name N-(2-methoxybenzyl)-1-(2-methoxy-4,5-methylenedioxyphenyl)-2-aminoethane
PubChem CID	177841592
Chemical and physical data
Formula	C18H21NO4
Molar mass	315.369 g·mol−1
3D model (JSmol)	Interactive image
SMILES COc1ccccc1CNCCc1cc2OCOc2cc1OC
InChI InChI=1S/C18H21NO4/c1-20-15-6-4-3-5-14(15)11-19-8-7-13-9-17-18(23-12-22-17)10-16(13)21-2/h3-6,9-10,19H,7-8,11-12H2,1-2H3 Key:XPZZCRFMAACBFQ-UHFFFAOYSA-N

2C2-NBOMe, also known as 2C-MMDA-2-NBOMe or NBOMe-MMDPEA-2, is a phenethylamine derivative from the 25-NB (NBOMe) family.¹² It is the NBOMe derivative of 2C-MMDA-2 (MMDPEA-2).²

It acts as a potent agonist at the serotonin 5-HT_2A receptor with weaker activity at 5-HT_2B and 5-HT_2C, and produces a head-twitch response in animal studies which often correlates with potential for psychedelic effects in humans.¹²

It is related in structure to psychedelic phenethylamine derivatives such as MMDA-2 and lophophine (MMDPEA) and is the first phenethylamine derivative with a methylenedioxy substitution on the phenyl ring but no alkyl substitution on the alpha carbon, that has been shown to produce psychedelic-appropriate responding in animals.¹²

The drug was first described in the literature by Jason Wallach and colleagues in 2022 and 2023.¹² It is a controlled substance in Canada under phenethylamine blanket-ban language.³ The drug is not an explicitly controlled substance in the United States,⁴ but could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.